DCE-MRI of osteogenic and Ewing’s sarcomas

Completed Research Project
Jonathan Dyke, Ph.D., DABMP
Related Institute: 
Last Updated: 
June 7, 2022

As a post-doctoral fellow, Dr. Dyke developed the first technique at Memorial Sloan Kettering Cancer Center (MSKCC) to non-invasively assess the grade of neoadjuvant chemotherapy in pediatric subjects with osteogenic or Ewing’s sarcomas using dynamic contrast enhanced (DCE)-MRI.  This technique is still in use and lets the orthopedic surgeon determine tumor response to chemotherapy prior to surgical resection.  Receiver operator characteristics provided optimal DCE-MRI cutoffs to assess varying tumor grades.  An additional paper from his group validated DCE-MRI contrast uptake with the histologically determined degree of vascular endothelial growth factor (VEGF) in excised tumor. 

Related Publications: (1) Dyke J.P., et al.,  Osteogenic and Ewing sarcomas: estimation of necrotic fraction during induction chemotherapy with dynamic contrast-enhanced MR imaging,  Radiology: 2003;228:271-278. (2) Hoang B.H., et al., VEGF expression in osteosarcoma correlates with vascular permeability by dynamic MRI, Clin. Orthop.: 2004;426:32-38.  

Associated Institute: MSKCC 

Jon Dyke Lab.mp4

Dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI)
Uptake of gadolinium in a region of interest (ROI) of a viable section of a pediatric osteogenic sarcoma—and a reference ROI in muscle. Pharmacokinetic modeling allows grading of tumor response to neoadjuvant chemo.

Weill Cornell Medicine
Department of Radiology
525 East 68th Street New York, NY 10065